Akers Biosciences Inc (AKR)

 
This US company’s shares are traded by us as on the LSE. Income from them will not be treated as eligible for a reduced rate of tax. Learn more

AKR Share PerformanceMore

52 week high255.00 01/12/16
52 week low86.00 24/02/17
52 week change -10.00 (-8.16%)
4 week volume61,229 28/02/17

Media for (AKR)

Presenter: Ray, Akers, Co-Founder & Executive Chairman
29/07/2014
Presenter: Ray, Akers, Co-Founder & Executive Chairman
16/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Akers Bio granted US patent

Akers Biosciences has announced that the US Patent and Trademark Office has allowed a patent covering the company's p...

US Patent for Akers Wellness Tests Cartridge

RNS Number: 0064X Akers Biosciences, Inc. 16 February 2017 Embargoed: 0700hrs 16 February 2017 Akers Biosciences, Inc. US Patent for Akers Wellness Tests Cartridge Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or "Akers Bio"), a developer of rapid health information technologies, announces that the United States Patent and Tradema...

Akers Bio revenues up 66%

Akers Biosciences expects total product revenue for the 12 months ended 31 December to be approximately $3.0m - 66% up ...

Trading Update

RNS Number: 6664V Akers Biosciences, Inc. 01 February 2017 1 February 2017 This announcement contains inside information Akers Biosciences, Inc. Trading Update Sales of PIFA Heparin PF/4 Rapid Assay Up 88% Over Prior Year Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ( " Akers Bio " or the "Company"), a developer of rapid health information t...

Akers Bio offering increased

Akers Biosciences says proceeds from its offering announced on 10 January are now expected to increase to $2,147,400, gros...

Issue of Equity

RNS Number: 0800U Akers Biosciences, Inc. 13 January 2017 13 January 2017 This announcement contains inside information Akers Biosciences, Inc. Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ( " Akers Bio " or the "Company"), a developer of rapid health information technologies, announces that, further to the public offering announce...

Issue of Equity

RNS Number: 7349T Akers Biosciences, Inc. 10 January 2017 10 January 2017 This announcement contains inside information Akers Biosciences, Inc. Filing of Supplement to Form S-3 Registration Statement Issue of Equity Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), ( " Akers Bio " or the "Company"), a developer of rapid health information technologies,...

Supplement to Form S-3 Registration Statement

RNS Number: 6004T Akers Biosciences, Inc. 09 January 2017 9 January 2017 This announcement contains inside information Akers Biosciences, Inc. Filing of Supplement to Form S-3 Registration Statement Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (" Akers Bio " or the "Company"), a developer of rapid health information technologies, announces that ...

Equity Research (AKR)

Akers Biosciences Inc.
18/08/2016
Physiomics* (PYC.L) 0.04p £1.22m The computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials...
Akers Biosciences Inc.
11/08/2016
ValiRx (Val.L) 39p £4.37m The life science company, which focuses on clinical stage cancer therapeutic development has received regulatory approval for its VAL401 Phase IIB Clinical Trial in Georgia...

Latest discussion posts More

  • RNS : new PIFA agreement

    Looks like a potentially lucrative agreement with a group of up to 300 New York hospitals to introduce the PIFA ...
    19-Dec-2016
    gretel
  • Exciting RNS just out

    Worth noting in particular that First Check are a subsidiary of the mighty Alere ...
    1-Dec-2016
    gretel
  • New interview with CEO

    Gormally comes across extremely well. Certainly lots to look forward to. And more optimism about the $2m Chinese sale coming through this quarter, which will be great news ...
    16-Nov-2016
    gretel

Users' HoldingsMore

Users who hold Akers Biosciences Inc also hold..
LLOYDS GRP.29%
ID:ISIN:GB00B142G99419%
BP16%
NATIONAL GRID16%
ALTONA12%

Codes & Symbols

ISINUS00973E1029
SymbolsAKR, LSE:AKR, AKR.L, AKR:LN, LON:AKR, XLON:AKR